Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Denali Therapeutics Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 213
- +2 vs. Q3 2021
- Shares held
- 85.3M
- +675.1K (+0.8%) vs. Q3 2021
- Total value
- $3.80B
- −$465.4M (−10.9%) vs. Q3 2021
- New holders
- 29
- 86 more added
- Sold out
- 27
- 62 more reduced
3 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 294 | $4.00B |
| Q1 2026 | 269 | $2.82B |
| Q4 2025 | 250 | $2.50B |
| Q3 2025 | 240 | $1.97B |
| Q2 2025 | 231 | $1.93B |
| Q1 2025 | 222 | $1.85B |
| Q4 2024 | 224 | $2.61B |
| Q3 2024 | 217 | $3.69B |
| Q2 2024 | 203 | $2.88B |
| Q1 2024 | 211 | $2.51B |
| Q4 2023 | 209 | $2.47B |
| Q3 2023 | 195 | $2.24B |
| Q2 2023 | 203 | $3.18B |
| Q1 2023 | 202 | $2.49B |
| Q4 2022 | 199 | $2.94B |
| Q3 2022 | 200 | $2.84B |
| Q2 2022 | 188 | $2.73B |
| Q1 2022 | 190 | $2.79B |
| Q4 2021 | 213 | $3.80B |
| Q3 2021 | 214 | $4.28B |
| Q2 2021 | 210 | $6.32B |
| Q1 2021 | 218 | $4.60B |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Denali Therapeutics Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Casdin Capital, LLC | 1,500,000 | $66.9M | 1.89% | −200,000−11.8% | Reduced |
| Geode Capital Management, LLC | 1,628,867 | $72.6M | 0.01% | +21,473+1.3% | Added |
| Credit Suisse AG | 1,963,648 | $87.6M | 0.07% | −18,825−0.9% | Reduced |
| Flagship Pioneering Inc. | 2,619,968 | $116.9M | 1.81% | −110,295−4.0% | Reduced |
| Gilder Gagnon Howe & Co LLC | 2,900,114 | $129.3M | 0.74% | +97,120+3.5% | Added |
| FMR LLC | 2,951,791 | $131.7M | 0.01% | +276,042+10.3% | Added |
| State Street Corp | 3,027,571 | $135.0M | 0.01% | +229,437+8.2% | Added |
| Price T Rowe Associates Inc | 4,635,433 | $206.7M | 0.02% | −122,532−2.6% | Reduced |
| Temasek Holdings (Private) Ltd | 5,369,487 | $239.5M | 0.86% | 00.0% | Unchanged |
| Crestline Management, LP | 7,705,039 | $343.6M | 25.82% | 00.0% | Unchanged |
| BlackRock Inc. | 8,110,822 | $361.7M | 0.01% | +549,985+7.3% | Added |
| Vanguard Group Inc | 8,161,530 | $364.0M | 0.01% | −6,953−0.1% | Reduced |
| Baillie Gifford & Co | 15,056,381 | $671.5M | 0.37% | +46,565+0.3% | Added |
| Pathway Capital Management, LP | 0 | $0 | 0.00% | −1,012,240−100.0% | Sold out |
| Hamilton Lane Advisors LLC | 0 | $0 | 0.00% | −396,944−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −96,868−100.0% | Sold out |
| Castleark Management LLC | 0 | $0 | 0.00% | −66,145−100.0% | Sold out |
| CastleArk Alternatives, LLC | 0 | $0 | 0.00% | −66,145−100.0% | Sold out |
| Soros Capital Management LLC | 0 | $0 | 0.00% | −54,000−100.0% | Sold out |
| University of Texas/Texas Am Investment Managment Co | 0 | $0 | 0.00% | −41,918−100.0% | Sold out |
| Tao Capital Management LP | 0 | $0 | 0.00% | −38,949−100.0% | Sold out |
| Duality Advisers, LP | 0 | $0 | 0.00% | −23,045−100.0% | Sold out |
| Polianta Ltd | 0 | $0 | 0.00% | −19,800−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −17,200−100.0% | Sold out |
| Old Mission Capital LLC | 0 | $0 | 0.00% | −15,522−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −15,200−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −7,017−100.0% | Sold out |
| Gotham Asset Management, LLC | 0 | $0 | 0.00% | −5,317−100.0% | Sold out |
| Altfest L J & Co Inc | 0 | $0 | 0.00% | −4,962−100.0% | Sold out |
| Xponance, Inc. | 0 | $0 | 0.00% | −4,315−100.0% | Sold out |
| Raymond James Financial Services Advisors, Inc. | 0 | $0 | 0.00% | −4,252−100.0% | Sold out |
| Pearl River Capital, LLC | 0 | $0 | 0.00% | −4,175−100.0% | Sold out |
| Broderick Brian C | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −3,669−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −1,186−100.0% | Sold out |
| Brewin Dolphin Ltd | 0 | $0 | 0.00% | −450−100.0% | Sold out |
| Sargent Bickham Lagudis LLC | 0 | $0 | 0.00% | −165−100.0% | Sold out |
| Atlas Private Wealth Advisors | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Institutional & Family Asset Management, LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |
| Sonora Investment Management, LLC | – | – | – | – | Not filed |
| Berman Capital Advisors, LLC | – | – | – | – | Not filed |